Clinical trials: Spinal Infection
Poliomyelitis
Duration of IPV Priming and Antibody Decay
This is an open-label randomized phase IV clinical trial assessing immunogenicity of poliovirus vaccines.Participants will be enrolled at 6 weeks of age and followed to 18 months of age.
- Trial name
- NCT03202719
- Testing
- Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age, Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age, Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
- Where
- 2 sites in Bangladesh
- Volunteers
- 1,645 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Postpolio Syndrome
Whole Body Vibration on Muscle Strength in Patients With Postpolio Syndrome
Post-polio syndrome (PPS) is a neurological disease that affects polio survivors at least 15 years after the initial polio infection.
- Trial name
- NCT04387864
- Testing
- Whole-body Vibration Device
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Koç University
Poliomyelitis
Immunogenicity of Intramuscular and Intradermal IPV
This is an open-label phase IV randomized clinical trial that will compare immune responses among infants who receive different dose schedules of either fractional dose or full dose inactivated poliovirus vaccine (IPV), delivered…
- Trial name
- IM and ID IPV (NCT04063150)
- Testing
- fIPV (0.1 mL) ID, fIPV (0.1mL) IM, fIPV (0.2mL) IM
- Where
- Bangladesh
- Volunteers
- 958 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of…
- Trial name
- SCOPE (NCT06895486)
- Testing
- Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2)
- Where
- 3 sites in Panama
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- PATH
Poliomyelitis
A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.
In April 2017, WHO recommended that a two-dose, Inactivated Poliovirus Vaccine, IPV-only schedule at 4 months and 8 months of age can be used after polio eradication, with a schedule seroconversion target of at least 90%.
- Trial name
- NCT03597919
- Testing
- Sabin IPV
- Where
- China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Diphtheria, Tetanus
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
This study aims to assess and confirm the adequate immunogenicity and safety profile of the Sanofi Pasteur's DTaP-Hep B-IPV-PRP-T fully liquid combined hexavalent vaccine administered in HIV-exposed uninfected infants and in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02817451
- Testing
- Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
- Where
- South Africa
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Polio, Immunization; Infection
Community Engagement and Conditional Incentives to Accelerate Polio
Immunization is one of the most cost-effective and successful public health strategy in reducing the health, economic and societal burden of many infectious diseases.
- Conditions
- Polio, Immunization; Infection, Incentives
- Trial name
- GLIDE (NCT05721274)
- Testing
- Community mobilization and Conditional community incentives
- Where
- Pakistan
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Diphtheria, Tetanus
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Venus (NCT02458183)
- Testing
- DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine
- Where
- 20 sites in South Korea, Thailand
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Arthritis, Arthritis, Reactive
The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
This study will evaluate patients with inflammatory forms of arthritis within the first year of onset. The study will attempt to clarify factors that may predict disease course such as evolution into rheumatoid arthritis (RA) or…
- Conditions
- Arthritis, Arthritis, Reactive, Arthritis, Rheumatoid, Reiter's Disease
- Trial name
- NCT00001375
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Poliomyelitis
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding, and genetic stability of two novel oral polio vaccine type 2 (nOPV2) vaccine candidates in IPV-primed…
- Trial name
- nOPV2M4a (NCT03430349)
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Polio, Polio Sero Conversion
To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
The objective of the projects is to Develop and implement a Package of interventions that will comprise of an augmented communication and counseling strategy coupled with private sector involvement and a combined Oral Polio…
- Conditions
- Polio, Polio Sero Conversion, Polio Sero Prevalence, Immunization Coverage
- Trial name
- NCT01908114
- Testing
- Enhanced Community mobilization, Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA
- Where
- Pakistan
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Level of Immunity Against Poliovirus Infection
Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals
The purpose of this study was to evaluated the effectiveness of inactivated poliovirus vaccine at a vaccine schedule that is commonly used in developing countries.
- Trial name
- NCT00260312
- Testing
- Inactivated Polio Vaccine given at an accelerated schedule
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pan American Health Organization
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Pertussis, Diphtheria
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTaP-IPV combined vaccines as a three-dose primary vaccination at 2, 4 and 6 months of age compared to commercially available…
- Conditions
- Pertussis, Diphtheria, Poliomyelitis, Tetanus
- Trial name
- NCT00319852
- Testing
- DTaP-IPV combined vaccine, DTaP vaccine
- Where
- South Korea
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- Sanofi
Poliomyelitis
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains
The purpose of this study is to evaluate the safety and the immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does.
- Trial name
- IPV (NCT01048190)
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strains)
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Incomplete Spinal Cord Injury, Transverse Myelitis
Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance
Robotic therapies aim to improve limb function in individuals with neurological injury. Modulation of robotic assistance in many of these therapies is achieved by measuring the extant volitional strength of limb muscles.
- Trial name
- NCT05249595
- Testing
- Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices, Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices, Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- North Carolina State University
Diphtheria, Hepatitis B
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
In this study, infants will be randomly allocated into three groups: one group of subjects will receive DTPa-HBV-IPV/Hib vaccine (new formulation) the second group of subjects will receive DTPa-HBV-IPV/Hib vaccine (current…
- Conditions
- Diphtheria, Hepatitis B, Poliomyelitis, Tetanus
- Trial name
- NCT00320463
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in Russia
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Primary Objective: To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00831311
- Testing
- DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- Where
- Argentina
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Acellular Pertussis
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants
The purpose of this study is to assess the immunogenicity and safety of DTPa-IPV/Hib when administered at 6, 10 and 14 weeks to healthy Indian infants, as per guidance from the Indian regulatory authority.
- Conditions
- Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT03128489
- Testing
- Infanrix-IPV/Hib
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Pertussis
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
PR5I, a hexavalent pediatric combination vaccine is being developed to reduce the number of injections during the first 2 years of life while providing a complete course of immunization against infection caused by H.
- Conditions
- Diphtheria, Pertussis, Polio, Hepatitis B
- Trial name
- NCT00362427
- Testing
- Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
- Where
- 8 sites in Canada
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company